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Abstract
The sequencing of the human genome in the early days of this millennium was greeted with great 
fanfare as this accomplishment was expected to revolutionize medicine and result in 
individualized treatments based on the genetic make-up of the patient. The ultimate promise of 
personalized medicine would be fulfilled with the identification of disease biomarkers that would 
be widely available for use in diagnosis and treatment. Progress, however, has been slow in 
providing disease biomarkers or approved diagnostic tests. This is true for major depressive 
disorder (MDD), despite its prevalence in the general population and the widespread acceptance of 
its biological basis. Studies using strategies like genome-wide association and candidate gene 
analyses have identified a number of possible biomarkers of MDD, including serum levels of 
neurotrophic factors, inflammatory cytokines and HPA axis hormones, but none have proven 
sufficiently powerful for clinical use. The lack of biologically based tests available for use in 
identifying patients with MDD is a significant impediment to personalized and more effective 
treatment, because it means diagnosis continues to be driven by subjective symptoms. While 
genetic studies of MDD have not yet led to diagnostic and treatment biomarkers, progress in 
determining the role of the genome in drug metabolism heralds the first effort in personalized 
prescribing for the antidepressants. The FDA suggested and approved genotyping tests for 
common variants of drug metabolism genes, such as the cytochrome p450s. By using these tests a 
physician can select an appropriate antidepressant for a given patient, as differences in clearance, 
half-life, and peak blood concentrations are controlled by genetic variability in drug metabolism. 
Personalization in drug choice can be achieved because these tests: (1) identify responders and 
non-responders; (2) provide alerts to possible adverse drug events; and (3) help optimize dose. 
Improved ways of diagnosing and prescribing effective treatments for MDD are needed, as the 
available methods are inadequate and symptom based. In the foreseeable future, further 
interrogation of the genome may serve as the basis for development of new personalized medicine 
strategies for diagnosis and treatment of MDD.
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“… the right pill at the right time for the right patient” is the promise of personalized 
medicine [1]. The sequencing of the human genome early in this millennium was lauded for 
the breadth of the scientific achievement and was expected to revolutionize medicine. 
Genomics would provide the links between our genes and biological events, whether normal 
or pathological. Armed with this blueprint, disease biomarker development would proceed 
rapidly and greatly improve clinical practice. Medical treatment would be individualized 
with targeted medicines based on the genetic and molecular profile of the patient. Here, we 
explore the challenges facing psychiatry with respect to a personalized medicine approach to 
major depressive disorder (MDD). Although often viewed as a single clinical condition, 
MDD is clinically heterogeneous with a high prevalence in primary care practice (~1 of 
every 10–20 patients). All ages and ethnicities are affected and currently diagnosis is 
dependent on the physician’s interpretation of the patients’ symptoms, because there is no 
biologically based diagnostic test for MDD. Our goal is to inform the “front-line” physician 
on the latest strategies for diagnosing and treating MDD from a personalized medicine 
perspective. We review how studies examining the contribution of genetics to development 
of MDD, the effectiveness of various antidepressant drugs, as well as the search for 
biomarkers, have fostered a more personalized medicine approach in MDD treatment. We 
discuss how pharmacogenetics may be contributing to a personalized medicine approach for 
the available MDD pharmacotherapies. Many individuals voice concerns to their primary 
care physician (PCP) long before they see a mental health professional [2,3].
2. The PCP and MDD in a Primary Care Patient Population
Due to its prominence (~20% in the general population) MDD often is referred to as the 
“common cold of psychiatry [2,4,5]. Worldwide, MDD causes significant economic ($83 
billion in the US alone) and psychosocial burdens due to the cost of hospitalization, lost 
work productivity and suicide. MDD is a lifelong disorder; it may be chronic or 
characterized by frequent recurrences with a mean of about 6 episodes in 15years [6]. Up to 
40% of sufferers remain untreated and suicide is a common consequence; about half of 
suicide victims visited a PCP within the month prior to their death [2,3,7]. With the advent 
of multiple SSRIs many more MDD patients now are being treated and maintained in 
primary care practices [4,8]. Learning how to recognize MDD, therefore, is a major obstacle 
facing the PCP.
Ideally, the PCP would have a sensitive and readily available blood test to aid in the 
diagnosis of MDD, but there are no accepted biomarkers or biologically based diagnostic 
tests. MDD symptoms further complicate diagnosis, because they can resemble normal 
emotions (e.g., sadness) that accompany many life events, but they are exaggerated and do 
not resolve when the cause ceases. Presentation often includes vague somatic symptoms 
(e.g., headache, fatigue) that may vary by gender and age, as well as racial heritage [2]. 
Thus, an Asian patient may complain of “tiredness” or “imbalance” while a Native 
American may be “heartbroken” [3]. Because of its prevalence the PCP should be alert to its 
presence in primary care settings. Many PCPs are reluctant to deal with mental illness, but 
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the topic should be discussed because the personal and societal burden of untreated 
depression is so costly.
3. Diagnosis & Treatment of MDD
Currently, the guidelines from the DSM-IV-R [9,10] are used to diagnose MDD. These 
guidelines include both inclusion and exclusion criteria as well as various qualifiers 
concerning the characteristics of the current episode and the course of the disorder. A major 
depressive episode is defined as a period of >2weeks where the patient experiences a 
depressed mood or the loss of interest or pleasure in nearly all activities (anhedonia), as well 
as difficulty in concentrating or sleeping, changes in appetite or weight, and thoughts of 
suicide or death. Symptoms lasting 2 or more years define chronic depression and cannot be 
due to alcohol, drugs, prescribed medication, a major medical condition or interspersed with 
periods of manic behavior. The constellation of symptoms also varies across patients. This 
hampers diagnosis and suggests that MDD is a heterogeneous disorder with possibly 
clinically distinct subpopulations or endophenotypes [11]. As no biologically based 
diagnostic tests are available, the subtypes of depression (e.g., seasonal affective disorder, 
postpartum, etc.) are based on the physician’s interpretation of the patient’s symptoms, 
observations of the patient, as well as the medical history of the patient and the patient’s 
family. Specific guidelines are available to help the PCP recognize and manage MDD 
[12,13]. Screening instruments are available to use in diagnosis, but they remain subjective. 
Objective biomarkers, despite years of searching, are not yet available. The current 
diagnostic tools are symptom driven and include various questions asked when completing 
the patient history (e.g., “Have you been feeling down, depressed, or blue over the last 
2weeks?”) or are found in patient-completed questionnaires and scales (e.g., Beck 
Depression Inventory; Patient Health Questionnaire-9-item [PHQ-9]) [14–16]. The high 
prevalence of MDD suggests that such screening questions and instruments should be a 
necessary component of every patient history. Additionally, the NIMH provides brochures 
(e.g., NIH Publication No. TR 10-4779) about MDD written in lay language that can be 
placed in the PCPs’ waiting and examination rooms. This provides the patient with easy 
access to information as well as opportunities for discussion between the patient and 
physician. Such materials are in the public domain and may be copied and reproduced 
without permission (nimhinfo@nih.gov).
Due to the lack of MDD biomarkers effective treatment is difficult at best and “trial and 
error” dominates much of the current clinical approach. Because the biological causes of 
MDD are still unknown, treatment tends to focus on symptom reduction rather than 
engendering remission of the disease. There are no diagnostic assessment tools that dictate 
the choice of one antidepressant over another and many placebo-controlled studies indicate 
that all the major classes can be effective [17]. This makes it difficult for the physician to 
predict which patients will display clinical improvement to a given drug [17,18]. Many 
patients stop taking their medication because of the significant amount of time, often 6–
12weeks, required for remission or symptomatic improvement. Patients can achieve the 
same degree of clinical effectiveness whether it occurs early or late in treatment; early 
success does not indicate greater effectiveness of the prescribed drug. Many experience 
difficulty with side effects (e.g., weight gain, decrease in libido) and fully 42% of patients 
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stop medication within the first 30days of treatment. Often patients do not respond to a 
given antidepressant and abandon their follow-up visits to the PCP. This limits their 
opportunity for treatment with a different agent or the addition of a second drug; both 
strategies are used in non-responders and can be effective [19]. Being able to predict non-
response early in treatment would help individualize drug selection but efforts directed 
towards this goal have yet to identify reliable predictors. Half of patients remain untreatable. 
Recent work, however, suggests that obtaining a combination of baseline features and early 
symptom changes post diagnosis, and initiation of medication, may have clinical benefit 
[20].
The focus on symptom reduction rather than remission makes it difficult for the PCP to tell 
the difference between the patient’s usual mental state and one that may be pathological [7]. 
The ACNP Task Force report discusses MDD in the context of response, remission, 
recovery, relapse and recurrence [6]. Thus, despite seemingly insurmountable roadblocks, 
strategies are available to help the PCP to better individualize treatment and to quickly 
provide effective pharmacotherapy [1]. The PCP should make the patient aware of the 
frequently lengthy interval between the beginning of treatment and symptom relief and/or 
remission. Success in treating MDD requires frequent and truthful communication between 
the patient and the PCP as well as shared decision-making concerning treatment options.
4. Genomics and MDD — Biomarkers, Diagnosis and Individualized 
Treatment
The NIH defines a biomarker as “a characteristic that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention [21]. Establishing correlations between disease and 
changes in biomarkers would certainly lead to better patient care and lower medical costs, 
but this goal has been difficult to achieve. Often, the term biomarker is used in an imprecise 
fashion, as evidenced by the over 150,000 published papers claiming the discovery of 
various disease biomarkers, but with only approximately 100 biomarkers in clinical use. 
Many biomarker discovery efforts are based on investigator-initiated academic research with 
examination of fewer than 100 samples. This hampers efforts to develop clinically useful 
biomarkers because of a general lack of standardization of methods, a lack of statistical 
power and a lack of stringency in case definition prior to sample collection. Ultimately, this 
poses a problem for the large-scale validation studies needed to evaluate candidate 
biomarkers for all diseases, not just MDD.
The wide acceptance of a genetic contribution to MDD has prompted the use of candidate 
gene and genome wide association strategies to search for contributing genes. Identification 
of genes that will lead to biomarkers useful in diagnosis and treatment is a goal yet to be 
realized. Other strategies used in the search for clinically viable biomarkers have 
concentrated on the further characterization of MDD using brain electroencephalographic 
and imaging techniques, as well as the measurement of presumed blood indicators such as 
inflammatory cytokines, HPA axis hormones, metabolic markers and growth factors [22,23]. 
The association between these various biochemical domains and MDD has sparked interest 
in the development of a serum-based, multi-analyte biomarker panel utilizing a composite 
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score rather than the traditional single analyte approach. Such panels remain under 
development [11,24].
In biomarker candidate studies, genes are selected for evaluation based on existing 
knowledge and, in the case of MDD, the emphasis has been on what is currently known 
about MDD and the primary targets and putative mechanism(s) of action of antidepressants. 
A group of subjects is genotyped for a certain gene variant and then the effect of that variant 
on the disease of concern is calculated. As targeting is done a priori, the information gained 
in these studies is limited and this strategy usually does not identify new avenues of 
investigation. Rather, it confirms or negates the influence of the targeted genes; often the 
predicted strong associations are not borne out. A case in point is the failure to find the 
expected strong impact of genes involved in serotonin synthesis on antidepressant response 
[25]. Meta-analysis of “candidate gene” studies, such as the many examining the variants of 
the serotonin transporter gene and depression, has found little support for the supposed link. 
Such analyses support the idea that these “false positives” may be the result of singling out 
just one gene for study when a large number of them may contribute to the disease, 
suggesting that genome-wide association studies are more likely to succeed in identifying 
biomarkers of disease [26] but see [27].
Genome-wide association studies are considered “hypothesis-free” as they evaluate all 
known genes and their association with MDD and/or the response to treatment. Thus, this 
strategy is expected to identify novel and clinically relevant genes with the discovery of 
genetic variants associated with pharmacologic response. The genetic influence in MDD is 
considered to be through multiple genes. Take, for example, the case for involvement of 
serotonin; there are at least 30 to 40 genes controlling the amount of it in the brain. If only 
one gene of interest is examined, the likelihood of a false positive result is high [26].
Just as there are no accepted diagnostic biomarkers of MDD available to the PCP, there are 
none to direct the choice of a given antidepressant class or to predict the success of a given 
drug. Experimental studies in animals and peripheral leukocytes from MDD patients find 
that genes for trophic factors (BDNF, FGF, VEGF) controlling cell proliferation, growth, 
and resiliency, as well as pathways controlling cell signaling, neurotransmitter transport and 
metabolism, are impacted by antidepressant treatment [28]. Studies examining quantitative 
electroencephalographic responses, brain imaging and various serum analytes provide new 
avenues of investigation in MDD, but to date they have provided no clinical utility for 
selecting an antidepressant or determining its effectiveness during treatment. The many 
studies linking depression to a variety of possible structural and functional biomarkers as 
well as genomic, proteomic, and metabolomic measures are thought provoking. They also 
suggest putative biomarkers may not be stable or invariant over time but may change with 
the course of the disease and with treatment. This suggests that their measurement at 
baseline or early in treatment may increase their predictive validity, but the clinical utility of 
this strategy in a primary care setting remains to be seen [7]. Of course, the cost–benefit of 
the development and use of a biomarker must be considered and factored into the treatment 
costs for MDD. For example, neuroimaging biomarkers would not be cost-effective.
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5. What the PCP Must Consider in Selecting an Antidepressant for MDD
Once MDD is diagnosed and the PCP decides to treat with an antidepressant, a number of 
hurdles must be faced in selecting the most suitable agent for a given patient. A high rate of 
therapeutic failure is the norm in MDD and, unfortunately, personalized medicine has yet to 
provide specific guidance for the PCP in terms of treatment selection. Finding an effective 
pharmacotherapy for a given patient is by “trial and error”. No clear evidence base exists to 
aid in choosing among existing medications to maximize benefit for the individual patient.
The pharmacological classes used to treat MDD include the tricyclics, the selective 
serotonin reuptake inhibitors (SSRI)s, and the serotonin norepinephrine reuptake inhibitors 
(SNRI)s, monoamine oxidase inhibitors (MAOs) and more recently developed classes that 
largely target melatonin and nicotine receptors [29,30]. All of these classes of 
antidepressants have been found to be effective. The trial and error process in drug selection, 
however, often means the first drug prescribed is not effective. Various drugs of the same or 
different class will need to be tried until symptom reduction or remission is achieved. The 
PCP should determine patient preference, past treatment history, family treatment history, 
clinical symptoms, the expected side effect profile and safety, as well as the possible need 
for medical/laboratory monitoring. One certainty the PCP faces in drug selection is that 
antidepressants have significant toxicity in some patients. As discussed below, unlike 
diagnosis and prediction of antidepressant effectiveness, genetic information and testing 
allow for some individualization of treatment with respect to avoiding toxicity.
6. Pharmacogenomics — The Genetics of Variable Drug Response & 
Treatment of MDD
MDD patients receiving identical antidepressant treatment do not have identical responses; 
this variation encompasses drug therapeutic efficacy as well as drug metabolism, 
pharmacokinetics and toxicity. Pharmacogenetics, the understanding of how an individual’s 
genetics affect the response to drugs, holds great promise for improving the outcome of 
MDD treatment by tailoring drug choice to a given patient’s genetic makeup [31–33]. While 
progress is being made, many pharmacogenomic efforts aimed at finding genes predictive of 
therapeutic response have not yet come to fruition. Despite a number of positive leads no 
robust genetic predictors of the therapeutic response to antidepressants have been found 
[25].
However, there is one area where pharmacogenetics has made a contribution in the 
personalization of antidepressant selection and that is in identifying the genes contributing to 
drug metabolism. This genetic variation between individuals contributes to differential blood 
levels of certain antidepressants resulting in considerable patient differences in drug 
exposure, clinical response and toxicity. Many commonly prescribed antidepressants are 
metabolized by the cytochrome P450 (CYP) liver enzyme system, specifically CYP2D6, 
CYP2C19, CYP3A4, and CYP2C9 [1]. Genetic variants of these enzymes result in large 
individual differences in clearance, half-life, and peak blood concentration that ultimately 
influence individual drug response and toxicity. For example, the number of functional 
CYP2D6 alleles will result in a fast metabolizer (2 alleles) or poor (0 alleles) phenotype 
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[34,35]. Genetic tests are available to determine the variants in individual patients and the 
US FDA recommends their use to better individualize treatment for many classes of drugs, 
including the antidepressants. Labels for many of the antidepressants now contain such 
information. It would be of maximum benefit to the patient if the PCP could consider 
comparative data on the relative efficacy, tolerability, safety and acceptability of all the 
various antidepressants to aid in drug choice. While this information often is lacking, it is 
likely that such comparative data will be available in the future owing in no small measure 
to advances in pharmacogenetic profiling [30].
7. Contribution of Pharmacogenetics & Metabolism to Therapeutic Efficacy 
of Antidepressants and Individualized Treatment
Drug regulatory bodies such the US FDA recommend that patients be genotyped for specific 
genetic biomarkers before a physician prescribes certain common medications, including 
many of the antidepressants. Despite the wide availability of tests for genotyping patients for 
genetic biomarkers related to drug actions, physicians have been reluctant to adopt such 
screening. To date there is little integration of pharmacogenetics into clinical practice. 
Despite this fact, efforts continue in obtaining and providing this type of information to the 
PCP. In part this is accomplished by frequent additions and updates to drug labels based on 
new pharmacogenomics information affecting safety or efficacy in certain patient 
populations [36]. To aid the PCP in using the current drug metabolism knowledge in 
choosing an antidepressant for an individual patient, there is valuable information regarding 
the pharmaco-metabonomic phenotyping issues in the Table of Pharmacogenomic 
Biomarkers in Drug Labels available at the FDA site (http://www.fda.gov/Drugs/
ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378). Additional valuable 
information is found at the Personalized Medicine Coalition site (http://www.dddmag.com/
Personalized-Medicine-Advances-But-Faces-Challenges111611) and in the guidelines made 
available by Clinical Pharmacogenetics Implementation Consortium (http://
www.pharmgkb.org). Physician education in the use of such genetic information and 
individualization of treatment are the goal of such sites. The fact that such information is 
readily available may herald the beginnings of success for personalized medicine in MDD. 
The PCP should be aware there are opposing views as to the real contribution of 
pharmacogenomics and genotyping to personalized medicine in clinical practice, as well as 
the cost-effectiveness of testing for these variants in dose adjustment. Many, including 
health-insurance companies and health care providers, still need to be persuaded that 
personalization in drug selection provides enough benefits to justify the cost. Further 
genotyping may have more clinical importance in diseases like MDD, where there are high 
rates of non-responders, as all methods providing information on individual drug response 
can be of clinical significance [34,37,38].
8. Summary
The PCP should be aware that MDD is relatively common in the general clinical practice 
patient population and it is costly in terms of lost function as well as mortality. Because 
there are no biomarkers for MDD, and no biologically based diagnostic tests in clinical use, 
the PCP must screen for this disorder on the basis of symptoms verbalized by the patients or 
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when gathering the initial or updated patient history. The PCP also should be aware that the 
symptoms of MDD vary by gender, age and ethnicity. The lack of biomarkers or diagnostic 
tests makes it is difficult for the PCP to predict antidepressant efficacy and to make 
appropriate drug selection. The PCP must advise patients that finding an effective treatment 
may require a considerable amount of time. This effort is time well used, as it will help 
decrease the number of patients who stop treatment. Currently, personalized medicine will 
not help the PCP in predicting which antidepressant will be effective for a given patient. 
However, existing information on genetic biomarkers and the availability of genotyping 
tests concerning genetic control of drug metabolism and associated toxicity will aid the PCP 
in selection of a safe antidepressant for that patient, and in minimizing factors that may 
influence patient compliance. A truly personalized medicine approach for MDD only will be 
achieved when identification of biomarkers of MDD results in the development of widely 
available and cost-effective diagnostic tests. Research directed toward the discovery of 
biomarkers of depression and treatment resistance is of the utmost importance in this 
endeavor.
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